UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported) – March 4, 2010
________________________
WEST PHARMACEUTICAL SERVICES, INC.
(Exact name of registrant as specified in its charter)
_____________________
| | | |
| Pennsylvania | 1-8036 | 23-1210010 |
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| | | |
| 101 Gordon Drive, PO Box 645, Lionville, PA | | 19341-0645 |
| (Address of principal executive offices) | | (Zip Code) |
610-594-2900
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or address, if changed since last report)
____________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01 Regulation FD Disclosure
In December 2009, the Company announced that it realigned its organization into two reporting segments now called “Pharmaceutical Packaging Systems” and “Pharmaceutical Delivery Systems.” The new reporting segments were effective beginning January 1, 2010. In order to assist investors in comparing 2010 performance with 2009 performance, the Company has presented unaudited 2009 quarterly and full-year segment data from its 2009 income statements as if the new reporting segments had been in effect at the beginning of 2009. A copy of this unaudited realigned segment data is attached to this report as Exhibit 99.1.
The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under that Act or the Securities Act of 1933.
Item 9.01 Financial Statements and Exhibits
| (d) | Exhibits | |
| | | |
| | Exhibit # | Description |
| | 99.1 | West Pharmaceutical Services, Inc. Unaudited 2009 Realigned Segment Data Showing “As-If” Effect of Realignment |
| | | |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
WEST PHARMACEUTICAL SERVICES, INC. |
| |
| /s/ John R. Gailey III |
| John R. Gailey III |
| Vice President, General Counsel and Secretary |
March 4, 2010
EXHIBIT INDEX
| Exhibit No. | Description |
| 99.1 | West Pharmaceutical Services, Inc. Unaudited 2009 Re-Presented Segment Data Showing “As-If” Effect of Realignment |
